Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

The combination met its primary endpoint of percent weight loss following an 8-week treatment period.

General practitioners will be able to prescribe the weight loss injection tirzepatide (Mounjaro) to “prioritised patient cohorts” from 23 June, NHS England has said. New interim commissioning guidance ...

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Telehealth firm Hims & Hers Health on Tuesday announced that it plans to sell Eli Lilly’s weight-loss drug. This comes after ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

The study concluded that treatment with SGLT-2I in conjunction with GLP-1RA may help to reduce the incidence of AF/flutter ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...